Observes nivolumab with chemotherapy before surgery for early lung cancer
Studies nivolumab plus chemotherapy given before surgery in adults with early lung cancer.
Plain-language title generated from the registry record
Registry title: An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany
Key facts
- Where
- Kempten (Allgäu), GermanySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in Germany with non-metastatic non-small cell lung cancer who are about to start nivolumab plus platinum-based chemotherapy before surgery.
- Age
- 18 years or older
- Sex
- Men and women can join
- Disease stage
- Non-metastatic non-small cell lung cancer that can be removed by surgery
- Earlier treatment
- The decision to start nivolumab plus platinum-based chemotherapy before surgery must be made as part of normal care, independent of the study
- Biomarker or test result
- Tumor PD-L1 expression of 1% or more (tumor proportion score, according to the EU-approved label)
Main reasons for not taking part
- Another current cancer, other than non-small cell lung cancer, that needs systemic or other treatment
- Other reasons not to use the treatment according to the Summary of product characteristics
Read by machine on 12 November 2026.
Where in Germany
- Klinikverbund AllgaeuKempten (Allgäu), GermanyContact: Christian Schumann, Site 0001Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT06169956
- Record updated
- 18 April 2024
- Original description
The purpose of this observational study is to collect and evaluate real-world data to assess the effectiveness of neoadjuvant nivolumab when given in combination with platinum-based chemotherapy in participants with early-stage, resectable non-small cell lung cancer (NSCLC) in GermanyRead full original descriptionShow less
Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy for Non-Metastatic NSCLC: A German, Nationwide, Prospective, Observational, Multicenter Study in Patients Scheduled to Receive 3 Cycles Nivolumab in Combination With Platinum-Based Chemotherapy for Non-Metastatic (Stage and PD-L1 Expression According to Label) Non-Small Cell Lung Cancer
The purpose of this observational study is to collect and evaluate real-world data to assess the effectiveness of neoadjuvant nivolumab when given in combination with platinum-based chemotherapy in participants with early-stage, resectable non-small cell lung cancer (NSCLC) in Germany
Inclusion: Aged 18 years or older; Diagnosis of non-metastatic non-small cell lung cancer with tumor Programmed death-ligand 1 (PD-L1) expression level of 1% or more (tumor proportion score (TPS); according to label approved in the European Union); Decision to initiate a neoadjuvant treatment with nivolumab plus platinum-based chemotherapy for treatment of non-small cell lung cancer according to current Summary of product characteristics and independent of the study; Willing to complete patient-reported outcome questionnaires and sufficient understanding of the German language; Signed written informed consent; Other criteria according to current Summary of product characteristics.
Exclusion: Current primary diagnosis of cancer other than non-small cell lung cancer that requires systemic or other treatment; Other contraindications according to current Summary of product characteristics.